OMNIlife science, Inc. Announces the Completion of 2000 APEX Robotic Technology Cases in US and Expansion into International Markets

Share Article

OMNI completed 2000 knee replacements in the USA utilizing the APEX Robotic Technology (“A.R.T. ™”) system and expanded deployment of the A.R.T. ™ system into Australian and Spanish Markets.

OMNIlife science, Inc., a company dedicated to the design, manufacture, and distribution of high quality orthopaedic medical devices developed specifically for total joint replacement, today announced the successful completion of 2000 knee replacements in the USA utilizing OMNI’s APEX Robotic Technology (“A.R.T. ™”) system as well as expansion of A.R.T. ™ system deployment into Australian and Spanish Markets.

APEX Robotic Technology™ system is a surgical navigation and Robotics platform that empowers the surgeon with intelligent instrumentation that allows intra-operative customization of total knee replacement procedure to accurately place the knee implant in each individual patient. The A.R.T. ™ system developed in conjunction with our sister company PRAXIM Inc. uses PRAXIM’s patented BoneMorphing® technology to create a precise virtual 3D model of the patient’s anatomy without preoperative CT or MRI imaging. The bone morphing technology in turn provides accurate positioning of a robotic bone cutting guide. A.R.T. ™ addresses key issues associated with conventional surgical procedures, including improving bone cutting precision, implant alignment and implant sizing.

OMNI’s President and CEO, George Cipolletti, noted; “Our progress with the ongoing development and market penetration with the Apex Robotic Technology platform combined with the APEX total knee replacement implant systems has progressed very well over the past two years. In cooperation with PRAXIM, we added multiple new A.R.T.™ surgical centers in Australia in 2012 and most recently in three new centers in Spain with very rapid acceptance by both hospitals and surgeons indicate that this system has potential to be adapted worldwide not just in the US market.”

Jan Koenig, M.D., Chief of Joint Replacement surgery and Director of Computer Assisted and Robotic Orthopaedic Surgery at Winthrop University Hospital, Long island, NY stated; “My recent experience leading surgeons through their first surgical cases with the APEX knee system implants and A.R.T.™ technology at one of the largest joint replacement centres in Spain, Hospital Vall d’Hebron in Barcelona, confirmed for me that this system can contribute to improving total knee replacement surgery even in very well established joint replacement centres that have not had access to robotic surgical technology in the past . The Spanish surgeons really appreciated the ease of use and advanced capabilities of the system and having a Spanish language version of the software available for their first cases demonstrated to them OMNI’s commitment to its international marketing efforts.”

About OMNIlife science, Inc.
OMNIlife science, Inc. was founded in 1999 as an organization committed to the design, manufacture and distribution of high quality orthopaedic devices. Our corporate headquarters are located in East Taunton, Massachusetts. Our products are prescribed by orthopaedic surgeons for their patients who require total joint replacement. OMNI is ISO 13485 certified and its products are FDA cleared and CE approved. OMNI is emerging as a leader in the development and marketing of joint replacement implant systems as well as advanced computer aided orthopaedic navigation, smart instrumentation and robotic surgery technology for joint replacement. We continue to challenge the design and functionality of our products based on continued advances in reconstructive surgical techniques, anatomic and biomechanical data, as well as input from surgeons and in cooperation with our partners; PRAXIM, Inc. and ENZTEC, Inc. Our corporate strategic objectives include continued growth through line extensions to our hip and knee product offerings as well as the introduction of new products that will complement our current product portfolio and allow us to provide new clinical options for our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Cabral
Visit website